Table 3.
Univariate and multivariate analyses for overall survival in the training cohort.
| Variables | Univariable analysis P | Multivariable analysis | |
|---|---|---|---|
| Hazard ratio (95% CI) | P | ||
| Immunotype | 0.001 | 0.002 | |
| Inflamed | Reference | ||
| Immune-excluded | 2.365 (1.734-7.616) | 0.015 | |
| Immune-desert | 4.655 (1.600-13.540) | 0.008 | |
| PD-L1 expression | 0.002 | 0.029 | |
| Low | Reference | ||
| High | 2.146 (1.067-4.310) | ||
| Sex | 0.392 | ||
| Male | |||
| Female | |||
| Age | 0.540 | ||
| <50 | |||
| ≥50 | |||
| HBV infection | 0.147 | ||
| Yes | |||
| No | |||
| Cirrhosis | 0.939 | ||
| Yes | |||
| No | |||
| ALT (U/L) | 0.631 | ||
| <40 | |||
| ≥40 | |||
| AFP (μg/L) | 0.141 | ||
| <20 | |||
| ≥20 | |||
| Grade | 0.001 | 0.028 | |
| G 1-2 | Reference | ||
| G 3-4 | 2.160 (1.085-4.292) | ||
| BCLC stage | <0.001 | 0.007 | |
| 0-A | Reference | ||
| B | 1.845 (1.104-4.237) | 0.032 | |
| C | 3.846 (1.304-11.363) | 0.015 | |
HBV, hepatitis B virus; ALT, alanine aminotransferase; AFP, alpha fetoprotein; BCLC, Barcelona Clinic Liver Cancer.